Beverages - Wineries & Distilleries
Compare Stocks
5 / 10Stock Comparison
WVVI vs NBY vs AYTU vs PRPH vs PAHC
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Drug Manufacturers - Specialty & Generic
Drug Manufacturers - Specialty & Generic
Drug Manufacturers - Specialty & Generic
WVVI vs NBY vs AYTU vs PRPH vs PAHC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Beverages - Wineries & Distilleries | Biotechnology | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $14M | $11M | $16M | $5M | $1.75B |
| Revenue (TTM) | $37M | $3M | $63M | $1M | $1.46B |
| Net Income (TTM) | $-1M | $3M | $-24M | $-42M | $92M |
| Gross Margin | 60.5% | 54.6% | 66.0% | 191.4% | 31.9% |
| Operating Margin | -2.4% | -273.0% | -13.9% | -25.0% | 11.6% |
| Forward P/E | — | — | — | — | 14.2x |
| Total Debt | $15.52B | $2M | $23M | $25M | $762M |
| Cash & Equiv. | $411M | $430K | $31M | $678K | $68M |
WVVI vs NBY vs AYTU vs PRPH vs PAHC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Willamette Valley V… (WVVI) | 100 | 47.9 | -52.1% |
| NovaBay Pharmaceuti… (NBY) | 100 | 0.0 | -100.0% |
| Aytu BioPharma, Inc. (AYTU) | 100 | 0.8 | -99.2% |
| ProPhase Labs, Inc. (PRPH) | 100 | 3.8 | -96.2% |
| Phibro Animal Healt… (PAHC) | 100 | 164.7 | +64.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: WVVI vs NBY vs AYTU vs PRPH vs PAHC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
WVVI ranks third and is worth considering specifically for income & stability.
- Dividend streak 4 yrs, beta -0.25, yield 100.0%
- 100.0% yield, 4-year raise streak, vs PAHC's 1.1%, (3 stocks pay no dividend)
NBY carries the broadest edge in this set and is the clearest fit for quality and efficiency.
- 114.6% margin vs PRPH's -38.7%
- 93.0% ROA vs PRPH's -63.5%, ROIC -217.0% vs -59.4%
AYTU is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.27, current ratio 1.26x
- Beta 1.27 vs NBY's 2.43
Among these 5 stocks, PRPH doesn't own a clear edge in any measured category.
PAHC is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 27.4%, EPS growth 18.8%, 3Y rev CAGR 11.2%
- 128.6% 10Y total return vs PRPH's 37.5%
- Beta 1.38, yield 1.1%, current ratio 2.76x
- 27.4% revenue growth vs WVVI's -100.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 27.4% revenue growth vs WVVI's -100.0% | |
| Quality / Margins | 114.6% margin vs PRPH's -38.7% | |
| Stability / Safety | Beta 1.27 vs NBY's 2.43 | |
| Dividends | 100.0% yield, 4-year raise streak, vs PAHC's 1.1%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +125.1% vs PRPH's -58.0% | |
| Efficiency (ROA) | 93.0% ROA vs PRPH's -63.5%, ROIC -217.0% vs -59.4% |
WVVI vs NBY vs AYTU vs PRPH vs PAHC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
WVVI vs NBY vs AYTU vs PRPH vs PAHC — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
PAHC leads in 3 of 6 categories
WVVI leads 2 • NBY leads 0 • AYTU leads 0 • PRPH leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
PAHC leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PAHC is the larger business by revenue, generating $1.5B annually — 1359.6x PRPH's $1M. NBY is the more profitable business, keeping 114.6% of every revenue dollar as net income compared to PRPH's -38.7%. On growth, PAHC holds the edge at +20.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $37M | $3M | $63M | $1M | $1.5B |
| EBITDAEarnings before interest/tax | $2M | -$8M | -$4M | -$22M | $220M |
| Net IncomeAfter-tax profit | -$1M | $3M | -$24M | -$42M | $92M |
| Free Cash FlowCash after capex | -$3M | -$7M | -$698,000 | -$23M | $47M |
| Gross MarginGross profit ÷ Revenue | +60.5% | +54.6% | +66.0% | +191.4% | +31.9% |
| Operating MarginEBIT ÷ Revenue | -2.4% | -2.7% | -13.9% | -25.0% | +11.6% |
| Net MarginNet income ÷ Revenue | -3.3% | +114.6% | -39.0% | -38.7% | +6.3% |
| FCF MarginFCF ÷ Revenue | -8.5% | -2.5% | -1.1% | -21.1% | +3.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -10.9% | -78.7% | -6.5% | -71.9% | +20.9% |
| EPS Growth (YoY)Latest quarter vs prior year | -94.1% | +63.3% | -3.0% | +54.3% | +7.4% |
Valuation Metrics
WVVI leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $14M | $11M | $16M | $5M | $1.7B |
| Enterprise ValueMkt cap + debt − cash | $15.1B | $13M | $7M | $29M | $2.4B |
| Trailing P/EPrice ÷ TTM EPS | -4.53x | -0.74x | -1.14x | -0.05x | 36.27x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | 14.23x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 4.85x |
| EV / EBITDAEnterprise value multiple | — | — | — | — | 15.65x |
| Price / SalesMarket cap ÷ Revenue | — | 1.16x | 0.23x | 0.74x | 1.35x |
| Price / BookPrice ÷ Book value/share | 0.00x | — | 0.82x | 0.31x | 6.15x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | 41.82x |
Profitability & Efficiency
PAHC leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
NBY delivers a 198.5% return on equity — every $100 of shareholder capital generates $198 in annual profit, vs $-6 for PRPH. WVVI carries lower financial leverage with a 0.23x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRPH's 3.34x. On the Piotroski fundamental quality scale (0–9), PAHC scores 5/9 vs PRPH's 1/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -1.8% | +198.5% | -172.1% | -6.1% | +30.8% |
| ROA (TTM)Return on assets | -1.1% | +93.0% | -20.0% | -63.5% | +6.7% |
| ROICReturn on invested capital | -2.6% | -2.2% | -33.5% | -59.4% | +9.8% |
| ROCEReturn on capital employed | -3.1% | -2.2% | -13.3% | -75.6% | +12.0% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 | 3 | 1 | 5 |
| Debt / EquityFinancial leverage | 0.23x | — | 1.21x | 3.34x | 2.67x |
| Net DebtTotal debt minus cash | $15.1B | $1M | -$8M | $24M | $694M |
| Cash & Equiv.Liquid assets | $411M | $430,000 | $31M | $678,000 | $68M |
| Total DebtShort + long-term debt | $15.5B | $2M | $23M | $25M | $762M |
| Interest CoverageEBIT ÷ Interest expense | -0.69x | -89.97x | -7.96x | -7.96x | 3.64x |
Total Returns (Dividends Reinvested)
PAHC leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PAHC five years ago would be worth $16,597 today (with dividends reinvested), compared to $13 for NBY. Over the past 12 months, PAHC leads with a +125.1% total return vs PRPH's -58.0%. The 3-year compound annual growth rate (CAGR) favors PAHC at 45.9% vs PRPH's -69.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -8.6% | -93.6% | -10.8% | -66.7% | +16.0% |
| 1-Year ReturnPast 12 months | -49.3% | +102.8% | +104.1% | -58.0% | +125.1% |
| 3-Year ReturnCumulative with dividends | -51.0% | -96.5% | +40.3% | -97.1% | +210.4% |
| 5-Year ReturnCumulative with dividends | -80.8% | -99.9% | -97.8% | -63.2% | +66.0% |
| 10-Year ReturnCumulative with dividends | -59.3% | -100.0% | -100.0% | +37.5% | +128.6% |
| CAGR (3Y)Annualised 3-year return | -21.2% | -67.4% | +12.0% | -69.4% | +45.9% |
Risk & Volatility
Evenly matched — WVVI and AYTU each lead in 1 of 2 comparable metrics.
Risk & Volatility
WVVI is the less volatile stock with a -0.25 beta — it tends to amplify market swings less than NBY's 2.43 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AYTU currently trades 80.5% from its 52-week high vs NBY's 1.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.25x | 2.43x | 1.27x | 2.28x | 1.38x |
| 52-Week HighHighest price in past year | $7.18 | $99.75 | $3.07 | $1.84 | $60.08 |
| 52-Week LowLowest price in past year | $2.49 | $1.11 | $1.20 | $0.07 | $19.00 |
| % of 52W HighCurrent price vs 52-week peak | +40.3% | +1.9% | +80.5% | +6.5% | +71.8% |
| RSI (14)Momentum oscillator 0–100 | 53.5 | 42.5 | 48.9 | 56.8 | 60.3 |
| Avg Volume (50D)Average daily shares traded | 3K | 595K | 42K | 105K | 302K |
Analyst Outlook
WVVI leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
For income investors, WVVI offers the higher dividend yield at 100.00% vs PAHC's 1.11%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | — | — | Buy |
| Price TargetConsensus 12-month target | — | — | — | — | $49.00 |
| # AnalystsCovering analysts | — | — | — | — | 13 |
| Dividend YieldAnnual dividend ÷ price | +100.0% | — | — | — | +1.1% |
| Dividend StreakConsecutive years of raises | 4 | — | — | 1 | 0 |
| Dividend / ShareAnnual DPS | $194.20 | — | — | — | $0.48 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
PAHC leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). WVVI leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.
WVVI vs NBY vs AYTU vs PRPH vs PAHC: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is WVVI or NBY or AYTU or PRPH or PAHC a better buy right now?
For growth investors, Phibro Animal Health Corporation (PAHC) is the stronger pick with 27.
4% revenue growth year-over-year, versus -100. 0% for Willamette Valley Vineyards, Inc. (WVVI). Phibro Animal Health Corporation (PAHC) offers the better valuation at 36. 3x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate Phibro Animal Health Corporation (PAHC) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — WVVI or NBY or AYTU or PRPH or PAHC?
Over the past 5 years, Phibro Animal Health Corporation (PAHC) delivered a total return of +66.
0%, compared to -99. 9% for NovaBay Pharmaceuticals, Inc. (NBY). Over 10 years, the gap is even starker: PAHC returned +128. 6% versus AYTU's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — WVVI or NBY or AYTU or PRPH or PAHC?
By beta (market sensitivity over 5 years), Willamette Valley Vineyards, Inc.
(WVVI) is the lower-risk stock at -0. 25β versus NovaBay Pharmaceuticals, Inc. 's 2. 43β — meaning NBY is approximately -1067% more volatile than WVVI relative to the S&P 500. On balance sheet safety, Willamette Valley Vineyards, Inc. (WVVI) carries a lower debt/equity ratio of 23% versus 3% for ProPhase Labs, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — WVVI or NBY or AYTU or PRPH or PAHC?
By revenue growth (latest reported year), Phibro Animal Health Corporation (PAHC) is pulling ahead at 27.
4% versus -100. 0% for Willamette Valley Vineyards, Inc. (WVVI). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to -166. 3% for ProPhase Labs, Inc.. Over a 3-year CAGR, PAHC leads at 11. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — WVVI or NBY or AYTU or PRPH or PAHC?
Phibro Animal Health Corporation (PAHC) is the more profitable company, earning 3.
7% net margin versus -788. 2% for ProPhase Labs, Inc. — meaning it keeps 3. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PAHC leads at 8. 5% versus -570. 6% for PRPH. At the gross margin level — before operating expenses — AYTU leads at 69. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — WVVI or NBY or AYTU or PRPH or PAHC?
In this comparison, WVVI (100.
0% yield), PAHC (1. 1% yield) pay a dividend. NBY, AYTU, PRPH do not pay a meaningful dividend and should not be held primarily for income.
07Is WVVI or NBY or AYTU or PRPH or PAHC better for a retirement portfolio?
For long-horizon retirement investors, Willamette Valley Vineyards, Inc.
(WVVI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 25), 100. 0% yield). NovaBay Pharmaceuticals, Inc. (NBY) carries a higher beta of 2. 43 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (WVVI: -59. 3%, NBY: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between WVVI and NBY and AYTU and PRPH and PAHC?
These companies operate in different sectors (WVVI (Consumer Defensive) and NBY (Healthcare) and AYTU (Healthcare) and PRPH (Healthcare) and PAHC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: WVVI is a small-cap income-oriented stock; NBY is a small-cap quality compounder stock; AYTU is a small-cap quality compounder stock; PRPH is a small-cap quality compounder stock; PAHC is a small-cap high-growth stock. WVVI, PAHC pay a dividend while NBY, AYTU, PRPH do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.